Market news
Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30. President and CEO Jacqueline Shea
Detailed price information for Inovio Pharma (INO-Q) from The Globe and Mail including charting and trades.
Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call
Detailed price information for Inovio Pharma (INO-Q) from The Globe and Mail including charting and trades.
Inovio: Q2 Earnings Snapshot
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.
Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara
Inovio stock fell after hours after pricing a $20 million public offering of common stock and warrants.
This is the newest page. Registered accounts read further back.